



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of  
ANDERSON et al.

Group Art Unit: 1644

Application No.: 09/758,173

Examiner: Phillip Gambel

Filed: January 12, 2001

Confirmation No.: 1215

For: METHODS FOR TREATING B CELL LYMPHOMA USING CD80-SPECIFIC  
ANTIBODIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed with a Request for Continued Examination. No certification or fee is required.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "T. A. Cawley, Jr.".

Thomas A. Cawley, Jr., Ph.D.,  
Registration Number 40,944

Date: May 6, 2004  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/CR:ntb



Atty. Dkt. No.	M#	Client Ref.
	037003-0276603	1995-30-0233D2
Applicant: ANDERSON et al.		
Appln. No.: 09/758,173		
Filing Date: January 12, 2001		
Examiner: Gambel, P.	Group Art Unit: 1644	

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Date: May 6, 2004

Page 1 of 3

**U.S. PATENT DOCUMENTS**


Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	4,816,397	03/1989	Boss	435	68	
BR	4,816,567	03/1989	Cabilly	530	387	
CR	5,116,964	05/1992	Capon	536	27	
DR	5,885,579	03/1999	Linsley			
ER	6,162,432	12/2000	Wallner			

**FOREIGN PATENT DOCUMENTS**


		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	FR	0 171 496 B1	05/1993	EP	Taniguchi				
	GR	0 173 494 A2	03/1986	EP	Morrison				
	HR	0 239 400 B1	08/1994	EP	Winter				
	IR	0 194 276 B1	08/1993	EP	Neuberger				
	JR	0 451 216 B1	10/1991	EP	Queen				
	KR	0 555 880 A2, A3	08/1993	EP	Aruffo				
	LR	0 682 040 A1	11/1995	EP	Queen				
	MR	2 177 096 A	03/1986	GB	Neuberger				
	NR	WO 92/06193	04/1992	WO	Gorman				
	OR	WO 93/09812	05/1993	WO	Lederman				
	PR	WO 94/28912	12/1994	WO	Thompson				
	QR	WO 95/06481	03/1995	WO	Noelle				
	RR	WO 95/06666	03/1995	WO	Noelle				
	SR	WO 98/19706	05/1998	WO	Anderson				

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

TR	Armitage, R.J., et al., Molecular and biological characterization of a murine ligand for CD40, Nature, 1992, 357:80-82.
UR	Asuma, M. et al., Functional Expression of B7/BB1 on Activated T Lymphocytes, J. Exp. Med., 1992, 177:845-850.
VR	Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol., 1981, 11:195-199.
WR	Blazar, B.R. et al., Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells, J Immunol., 1996, 157:3250-3259.
XR	Capon, D.J., et al., Designing CD4 immunoadhesins for AIDS therapy, Nature, 1989, 337, 525-531.
YR	Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett., 1985, 188(1):33-36.
ZR	Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 1994, 145(3), 200-205 & 244-249.
AAR	Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 1993, 261:1328-1330.



BBR	Freeman, G.J. et al., Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice, Science, 1993, 262:907-909.
CCR	Freeman, G.J. et al., B7, A new member of the Ig Superfamily with unique expression on activated and neoplastic B cells, J of Immunol., 1989, 143:2714-2722.
DDR	Freeman, G.J. et al., Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation, Science, 1993, 262:909-911.
EEF	Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
FFR	Gottlieb, A. et al., Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol., 2000, 114:840, Abstract No. 546.
GGR	Gottlieb, A. et al., Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody, J Am Acad Dermatol., 2002, 47:692-700.
HHR	Guinan, E.C. et al., Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood, 1994, 84:3261-3282.
IIR	Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 1991, 636:251-265.
JJR	Hariharan et al., "In vitro and in vivo studies demonstrating the effectiveness of IDEC-114 and rituximab (Rituxan®) in therapy of B-cell lymphoma in experimental models; Confidential Report (laboratory notebook and data binder 2552, 2646, 2665, and 2671)," June 29, 2001.
KKR	Hathcock, K.S. et al., Identification of an alternative CTLA-4 ligand costimulatory for T cell activation, Science, 1993, 262:905-907.
LLR	Hollenbaugh, D., et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, The EMBO J., 1992, 11(12):4313-4321.
MMR	Janeway, C.A. et al., Signals and Signs for Lymphocyte Responses, 1994, 76:275-285.
NNR	Kahan, B.D., Immunosuppressive therapy, Curr Opin Immunol., 1992, 4:553-560.
OOR	Karpus, W.J., et al., CD4+ suppressor cells differentially affect the production of IFN- $\gamma$ by effector cells of experimental autoimmune encephalomyelitis, J. Immunol., 1989, 143:3492-3497.
PPR	Laman, J., et al., The role of gp39 (CD40 ligand) in EAE and MS, Journal of Neuroimmunology, 1994, 54(1-2):175.
QQR	Lederman, S., et al., Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), J. Exp. Med., 1992, 175:1091-1101.
RRR	Lider, O., et al., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein, J. Immunol., 1989, 142:748-752.
SSR	Linsley, P.S. et al., The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol., 1993, 11:191-212.
TTR	Linsley, P.S. et al., T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1, Proc. Natl. Acad., 1990, 87:5031-5035.
UUR	McCafferty, J., et al., Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 1990, 348:552-554.
VVR	Miller, A., et al., Antigen-driven bystander suppression after oral administration of antigens, J. Exp. Med., 1991, 174:791-798.
WW	Mokhtarian, F., et al., Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice, Nature, 1984, 309:356-358.
XXR	Morrison, S., et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. U.S.A., 1985, 81:6851-6855.
YYR	Nickloff, B.J. et al., T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28, Blood, 1994, 83:2580-2586.
ZZR	Noelle, R.J., et al., A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells, Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
AAAI	Olsson, L., et al., Human-human monoclonal antibody-producing hybridomas: technical aspects, Meth, Enzymol., 1982, 92:3-17.
BBBI	Perrin, P.J. et al., Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis, J Neuroimmunol., 1996, 65:31-39.
CCC	Pesoa, S.A., et al., Regulation of experimental allergic encephalomyelitis. Part 5. Role of the recipient in suppressor cell induction, J. Neuroimmunol, 1984, 7:131-135.

	DDD	Pettinelli, C.B., et al., Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after <i>in vitro</i> activation of lymph node cells by myelin basic protein: requirement for $\text{Lyt } 1^+ 2^-$ T lymphocytes, J. Immunol., 1979, 127:1420-1423.
	EEE	Sobel, R.A., et al., Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein, J. Neuropathol. Exp. Neurol., 1990, 49(5):468-479.
	FFF	Stamenkovic, I., et al., A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, The EMBO J., 1989, 8(5),1403-1410.
	GGG	Suvas, S. et al., Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma, J Biol Chem., 2002, 277:7766-7775.
	HHH	Takeda S., et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences, Nature, 1985, 314(4):452-454.
	IIIR	Teng, N. H. et al., Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. U.S.A., 1983, 80:7308—7312.
	JJJR	Tuohy, V.K., et al., Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice, J. Immunol., 1989, 142:1523-1527.
	KKK	Valle, A. et al., mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells, Immunology, 1990, 69:531-535.
	LLL	Van der Veen, R. C. et al., The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein, J. Neuroimmunol., 1989, 21:183-191.
	MMM	Ward, E.S., et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, 1989, 341:544-546.
	NNN	Ward, P.A., et al., Blocking of adhesion molecules in vivo as anti-inflammatory therapy, Ther Immunol., 1994, 1:165-171.
	OOO	Yi-qun, Z. et al., Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens, Int Immunol., 1996, 8:37-44.
Examiner		Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		